OncoHealth

OncoHealth

OncoHealth is developing high-throughput screening products utilizing its own proprietary biomarkers for direct detection of human papilloma virus (HPV) E6E7 oncoproteins present during the development of cervical and other HPV-related cancers.

Related Articles & Links

October 2014 Cervical Cancer Screening – New Advances Bring New Controversies

April 2013 HPV testing and cancer – will E6E7 change the paradigm

December 3, 2012 New data demonstrate ability of OncoHealth’s HPV E6/E7 assays to help differentiate cervical disease from clinically insignificant HPV infections.

December 2011 OncoHealth Takes on HPV Testing Market with Protein-Based Assay

November 2011 Can E6E7 Alter the Competitive Balance in the Crowded HPV Test Market?

November 2011 Developments in Cervical Cancer Testing

November 2011 Issue Cover with OncoHealth callout. Medical Laboratory Observer.

November 2011 Executive Snapshot: OncoHealth to provide patient- and lab-friendly assays

September 21, 2011 New data suggest OncoHealth’s HPV E6 and E7 tests can distinguish cervical disease from clinically insignificant HPV infection

May 3, 2011 Sand Hill Angels and Life Science Angels Anchor Oversubscribed $1.6 Million Investment in OncoHealth Corporation

Jan 7, 2011 Personalized medicine expected to boom in 2011 | Silicon Valley / San Jose Business Journal

Our Philosophy

We focus on portfolio returns, big opportunities, high-quality team, and financials that demonstrate a deep understanding of the business. We look for companies where our experience and expertise can add value to produce better outcomes for both entrepreneurs and our investments.

Our Networks

Relationships and people matter. Over the decades, we have developed personal relationships with other quality investors (both Angels and VCs), service providers, and domain experts. If we do not know the answer, we know someone who does.

Our Mentorship

When the company wins, we all win. To maximize success, we often serve as advisors or board members. Both art and science are involved in building a supportive and useful board as well as maintaining solid investor relations. Good financial discipline lays the foundation for success and informs company strategy.

Our Strategy

We like healthcare, especially digital health, but also diagnostics, devices, and bio/genomics. For funding, we often co-invest with other investors and are happy to lead investment rounds. We know term sheets and what drives syndicated investment rounds.
Scroll to top